Mirum named Rob Myers as chief medical officer, effective Sept. 21, 2026, to lead global medical and clinical development.
Myers joins from OrsoBio, where he served as chief medical officer and head of development.
He previously held senior roles at Gilead Sciences, overseeing clinical development across liver fibrosis, cholestatic liver diseases, gastrointestinal inflammation.
Outgoing chief medical officer Joanne Quan will depart the company.
MIRM•
